Please assess the completion status of the following clinical trial:

Trial Title: Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Subject Inclusion Criteria~To be eligible for enrollment, patients must meet all of the following criteria:~1. At least 18 years of age~2. Diagnosed with compensated chronic HCV genotype 1 infection that has not been treated with interferon, peginterferon, ribavirin or any experimental therapy for \>28 days~2a Serum HCV RNA \>2000 copies/mL (780 IU/mL) 2b Liver biopsy performed within 3 years prior to screening consistent with chronic HCV infection 2c Criteria for compensated HCV infection, including normal prothrombin time, serum albumin and bilirubin levels (unless due to non-hepatitis factors) and no history or evidence of bleeding esophageal varices, ascites, or hepatic encephalopathy~3 History of alanine aminotransferase (ALT) elevation either within 6 months prior to screening, at screening, or on retest 2 weeks after a negative screening test, or histologic evidence of HCV infection and a detectable viral load~4 Platelet count ≥90,000/mm3~5 Absolute neutrophil count ≥1200/mm3~6 Hemoglobin ≥12.0 g/dL for females or ≥13.0 g/dL for males~7 Antinuclear antibody (ANA) titer ≤1:320~8 Serum creatinine \<1.5 mg/dL~9 HbA1c ≤8.5% for diabetic patients~10 Normal or adequately controlled TSH on prescription medication~11 Alpha fetoprotein (AFP) \<20 ng/mL or hepatocellular carcinoma ruled out (ultrasound, CT or MRI scan) within 6 months prior to the study (Patients with an AFP \>20 ng/mL must have ongoing hepatocellular carcinoma screening during study as part of the patient's routine medical care)~12 All other clinical laboratory values within normal limits, unless judged not clinically significant by the investigator~13 Sterile or infertile (defined as vasectomy, tubal ligation, postmenopausal, or hysterectomy), or willing to use an approved method of double-barrier contraception (hormonal plus barrier or barrier plus barrier, eg, diaphragm plus condom) from the time of first dose administration until 6 months after the last dose~14 Capable of understanding instructions, adhering to study schedules and requirements, and willing to provided informed consent~Subject Exclusion Criteria~Patients who have any of the following during the screening or Day 1 visit are not eligible for enrollment in this study:~1. Positive HIV or HbsAg serology~2. Severe psychiatric or neuropsychiatric disorders including severe depression, history of suicidal ideations or suicide attempt(s). (This would include patients with a history of suicidal ideations or suicide attempt(s) that occurred when the patient was a minor or many years ago; if the event occurred while under the influence of alcohol or drugs; if the suicidal ideations or suicide attempt(s) were connected to a traumatic event; if the patient was not hospitalized or treated; if the patient has obtained psychiatric clearance for treatment)~3. History or clinical manifestations of significant metabolic, hematological, pulmonary, ischemic or unstable heart disease, gastrointestinal, neurological, renal, urological, endocrine, ophthalmologic (including severe retinopathy), or immune mediated disease~4. History of thalassemia or other hemoglobinopathies (even if the hemoglobin is normal)~5. Chronic hepatic disease other than hepatitis C~6. Organ or bone marrow transplant~7. Chronic (greater than 30 days) use of immunosuppressive medications including steroids in doses equivalent to 10 mg of prednisone or higher, 30 days prior to and anytime during the course of the study~8. Female patients who are breast-feeding or have a positive pregnancy test at any time during the study~9. Males whose female partners are pregnant~10. Patients who have had a malignancy diagnosed and/or treated within the past 5 years, except for localized squamous or basal cell cancers treated by local excision~11. Patients who have participated in a clinical trial and have received an investigational drug within 30 days prior to screening~12. History of alcoholism or drug addiction 1 year prior to screening~13. The use of methadone, buprenorphine or any similar drug, regardless of the prescribed indication or the length of time the patient has been on the drug~14. Chronic (\>4 weeks duration) diarrhea, including irritable bowel disease~15. Fibrosis score F4 (cirrhosis) based on Metavir or equivalent index~16. Weight \>128 kg or \<40 kg~17. Patients infected with mixed HCV genotypes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1: Drug (Type: EXPERIMENTAL): Oral taribavirin tablet 20 mg/kg/day (Actual doses were 20-24 mg/kg/day) BID plus weekly subcutaneous injections of peginterferon alfa-2b (1.5 ug/kg/wk)
- Group 2: Drug (Type: EXPERIMENTAL): Oral taribavirin tablet 25 mg/kg/day (Actual doses were 25-29 mg/kg/day) BID plus weekly subcutaneous injections of peginterferon alfa-2b (1.5 ug/kg/wk)
- Group 3: Drug (Type: EXPERIMENTAL): Oral taribavirin 30 mg/kg/day (Actual doses were 30-34 mg/kg/day) BID plus weekly subcutaneous injections of peginterferon alfa-2b (1.5 ug/kg/wk)
- Group 4: Drug (Type: ACTIVE_COMPARATOR): Oral ribavirin 800 mg/day (body weight \<65 kg), 1000 mg/day (body weight 65-84 kg), 1200 mg/day (body weight 85-104 kg) or 1400 mg/day (body weight greater than or equal to 105 kg) BID plus weekly subcutaneous injections of peginterferon alfa-2b (1.5 ug/kg/wk)

Based on this trial design, predict the completion outcome and termination type (if applicable).